{"id":384788,"date":"2020-11-19T07:03:15","date_gmt":"2020-11-19T12:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384788"},"modified":"2020-11-19T07:03:15","modified_gmt":"2020-11-19T12:03:15","slug":"eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/","title":{"rendered":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc.\u00a0(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company\u2019s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on <strong>Friday, <\/strong><strong>December 4<\/strong><strong>, 2020, at 12:00 p.m. ET<\/strong>.<\/p>\n<p align=\"justify\">Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; and Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Houston, Deputy Chair For Ophthalmology, Blanton Eye Institute.<\/p>\n<p align=\"justify\">To access the event, please dial (877) 870-4263 from the U.S. and Canada or (412) 317-0790 from international locations at least 10 minutes prior to the start time and ask to be joined to the EyePoint call. A live video webcast will be available on the Investor Relations section of the corporate website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mQZhR90zmgxHRcsa2S6N1PNtiLNo6Jj_T77qr4QfVqHMT4Rlv_EquQosZqXMOPWEb_0JqNfWHG636gHmrrEP5ypOa4BrQ2RqUZiXIuu5QG8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.eyepointpharma.com<\/a>. A webcast replay will also be available on the corporate website at the conclusion of the call.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>EyePoint<\/strong><br \/>\n        <strong> Pharmaceuticals<\/strong><br \/>\n        <br \/>EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU\u00ae, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ\u00ae, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company&#8217;s pipeline leverages its proprietary bioerodible Durasert\u00ae technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=viYXpeI40Dh3rNeOs7JZMhVuyNPo2DexO5CEuPiwjn26jacV441x61rTKbIaCuOWg2WxR18tWgDLZJS-wOhVzqwxQUP8-xqRGo9_z3XaQv8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.eyepointpharma.com<\/a>\u00a0and connect on Twitter and LinkedIn.<\/p>\n<p align=\"justify\">\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Investors:<br \/>Argot Partners<br \/>Sam Martin or Joe Rayne <br \/>212-600-1902 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hSz7EO1FOvjuEZJzLq0D3TKZNKyArAFyruGv64xkB3mxDM945xo93c8WKLnWIqols9TaaRSmupoJ0VCZQwDtIRZMEXOtNEUbM_IlvIykmLkIK927YEymf9TpT421KoK3\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">eyepoint@argotpartners.com<\/a><\/p>\n<p align=\"justify\">Media:<br \/>Thomas Gibson<br \/>201-476-0322<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZXDJBSiqxuyGqRcJXEnHHbvEOT24sJaYssOOB67-3vtmon23mRhEvZOiLV81euYOFgTCD-0fAKHqeaBCqdGDEZ0vu674EAUrGJ1EViXTiDKae3AxOxidELcQCXb5w5U7\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tom@tomgibsoncommunications.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e33ca737-c512-4ba1-93a6-e967b12b78bb\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc.\u00a0(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company\u2019s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET. Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384788","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc.\u00a0(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company\u2019s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET. Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; &hellip; Continue reading &quot;EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T12:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4\",\"datePublished\":\"2020-11-19T12:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/\",\"name\":\"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\",\"datePublished\":\"2020-11-19T12:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk","og_description":"WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc.\u00a0(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company\u2019s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET. Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; &hellip; Continue reading \"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T12:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4","datePublished":"2020-11-19T12:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/"},"wordCount":390,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/","name":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=","datePublished":"2020-11-19T12:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc1OCMzODM0NDk0IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-drug-delivery-for-wet-amd-on-december-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384788"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384788\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}